Two distinct tyrosine-based motifs enable the inhibitory receptor FcγRIIB to cooperatively recruit the inositol phosphatases SHIP1/2 and the adapters Grb2/Grap

被引:40
作者
Isnardi, I
Lesourne, R
Bruhns, P
Fridman, WH
Cambier, JC
Daëron, M
机构
[1] Inst Pasteur, Dept Immunol, Unite Allergol Mol & Cellulaire, F-75015 Paris, France
[2] Inst Rech Biomed Cordeliers, Lab Immunol Cellulaire & Clin, INSERM, U255, F-75006 Paris, France
[3] Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80262 USA
[4] Natl Jewish Med & Res Ctr, Denver, CO 80262 USA
[5] Inst Pasteur, Unite Allergol Mol & Cellulaire, F-75015 Paris, France
关键词
D O I
10.1074/jbc.M410261200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
FcgammaRIIB are low-affinity receptors for IgG that contain an immunoreceptor tyrosine-based inhibition motif (ITIM) and inhibit immunoreceptor tyrosine-based activation motif (ITAM)-dependent cell activation. When co-aggregated with ITAM-bearing receptors, FcgammaRIIB become tyrosyl-phosphorylated and recruit the Src homology 2 (SH2) domain-containing inositol 5'-phosphatases SHIP1 and SHIP2, which mediate inhibition. The FcgammaRIIB ITIM was proposed to be necessary and sufficient for recruiting SHIP1/2. We show here that a second tyrosine-containing motif in the intracytoplasmic domain of FcgammaRIIB is required for SHIP1/2 to be coprecipitated with the receptor. This motif functions as a docking site for the SH2 domain-containing adapters Grb2 and Grap. These adapters interact via their C-terminal SH3 domain with SHIP1/2 to form a stable receptor-phosphatase-adapter trimolecular complex. Both Grb2 and Grap are required for an optimal coprecipitation of SHIP with FcgammaRIIB, but one adapter is sufficient for the phosphatase to coprecipitate in a detectable manner with the receptors. In addition to facilitating the recruitment of SHIPs, the second tyrosine-based motif may confer upon FcgammaRIIB the properties of scaffold proteins capable of altering the composition and stability of the signaling complexes generated following receptor engagement.
引用
收藏
页码:51931 / 51938
页数:8
相关论文
共 47 条
[1]   Essential role for the C-terminal noncatalytic region of SHIP in FcγRIIB1-mediated inhibitory signaling [J].
Aman, MJ ;
Walk, SF ;
March, ME ;
Su, HP ;
Carver, DJ ;
Ravichandran, KS .
MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (10) :3576-3589
[2]   CYTOPLASMIC DOMAIN HETEROGENEITY AND FUNCTIONS OF IGG FC-RECEPTORS IN LYMPHOCYTES-B [J].
AMIGORENA, S ;
BONNEROT, C ;
DRAKE, JR ;
CHOQUET, D ;
HUNZIKER, W ;
GUILLET, JG ;
WEBSTER, P ;
SAUTES, C ;
MELLMAN, I ;
FRIDMAN, WH .
SCIENCE, 1992, 256 (5065) :1808-1812
[3]   Spontaneous autoimmune disease in FcγRIIB-deficient mice results from strain-specific epistasis [J].
Bolland, S ;
Ravetch, JV .
IMMUNITY, 2000, 13 (02) :277-285
[4]   SHIP modulates immune receptor responses by regulating membrane association of Btk [J].
Bolland, S ;
Pearse, RN ;
Kurosaki, T ;
Ravetch, JV .
IMMUNITY, 1998, 8 (04) :509-516
[5]   Differential regulation of B cell development, activation, and death by the Src homology 2 domain-containing 5′ inositol phosphatase (SHIP) [J].
Brauweiler, A ;
Tamir, I ;
Dal Porto, J ;
Benschop, RJ ;
Helgason, CD ;
Humphries, RK ;
Freed, JH ;
Cambier, JC .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (09) :1545-1554
[6]   Partially distinct molecular mechanisms mediate inhibitory FcγRIIB signaling in resting and activated B cells' [J].
Brauweiler, A ;
Tamir, I ;
Marschner, S ;
Helgason, CD ;
Cambier, JC .
JOURNAL OF IMMUNOLOGY, 2001, 167 (01) :204-211
[7]   Molecular basis of the recruitment of the SH2 domain-containing inositol 5-phosphatases SHIP1 and SHIP2 by FcγRIIB [J].
Bruhns, P ;
Vély, F ;
Malbec, O ;
Fridman, WH ;
Vivier, E ;
Daëron, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (48) :37357-37364
[8]  
Bruhns P, 1999, J IMMUNOL, V162, P3168
[9]   ANALYSIS OF THE INTERACTION OF ZAP-70 AND SYK PROTEIN-TYROSINE KINASES WITH THE T-CELL ANTIGEN RECEPTOR BY PLASMON RESONANCE [J].
BU, JY ;
SHAW, AS ;
CHAN, AC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (11) :5106-5110
[10]  
Burshtyn DN, 1999, J IMMUNOL, V162, P897